Published in Clin Neuropharmacol on December 01, 1995
NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology (Berl) (2009) 0.81
Activation of a nitric-oxide-sensitive cAMP pathway with phencyclidine: elevated hippocampal cAMP levels are temporally associated with deficits in prepulse inhibition. Psychopharmacology (Berl) (2004) 0.81
Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) (2004) 0.80
Inhibition of neuronal nitric oxide synthase prevents alterations in medial prefrontal cortex excitability induced by repeated cocaine administration. Psychopharmacology (Berl) (2010) 0.80
Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice. Psychopharmacology (Berl) (2013) 0.76
Long-term imipramine treatment increases nitrate levels in the rat hypothalamus. Cell Mol Neurobiol (2003) 0.75
Sun gazing by psychiatric patients. Am J Psychiatry (1990) 2.73
d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology (1996) 1.54
An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol (1991) 1.41
Glycine prodrug facilitates memory retrieval in humans. Neurology (1991) 1.39
A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol (1989) 0.99
Preattentive and attentive eye movements during visual scanning of a cocaine cue: correlation with intensity of cocaine cravings. J Neuropsychiatry Clin Neurosci (1997) 0.98
A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol (2001) 0.98
Caregiver's anticipatory grief in dementia: a pilot study. Int J Aging Hum Dev (1991) 0.97
Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol (1993) 0.97
Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol (1994) 0.97
Transient compulsive foraging behavior associated with crack cocaine use. Am J Psychiatry (1993) 0.95
The effects of adenosine A3 receptor stimulation on seizures in mice. Eur J Pharmacol (1995) 0.93
Regulation of growth and morphological modulation of HeLa65 cells in monolayer culture by dibutyryl cyclic AMP, butyrate and their analogs. J Cell Physiol (1975) 0.91
Clock drawing in the screening assessment of cognitive impairment in an ambulatory care setting: a preliminary report. Gen Hosp Psychiatry (1992) 0.90
Measures of visual scanning as a predictor of cocaine cravings and urges. Biol Psychiatry (1993) 0.89
Impaired motor skill learning in schizophrenia: implications for corticostriatal dysfunction. Biol Psychiatry (1996) 0.87
Gaze discrimination in patients with schizophrenia: preliminary report. Am J Psychiatry (1994) 0.87
Correlation between antisaccade and Wisconsin Card Sorting Test performance in schizophrenia. Am J Psychiatry (1993) 0.87
Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res (1989) 0.86
Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals. Biol Psychiatry (1983) 0.85
Increased alkaline phosphatase activity in HeLa cells mediated by aliphatic monocarboxylates and inhibitors of DNA synthesis. Biochim Biophys Acta (1977) 0.85
Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol (1997) 0.85
Toward a neuropsychology of memory in schizophrenia. Psychopharmacol Bull (1992) 0.85
Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. Clin Neuropharmacol (1995) 0.84
Behavioral approaches to the functional assessment of NMDA-mediated neural transmission in intact mice. Clin Neuropharmacol (1997) 0.83
Status of cholinesterase activities in blood in neuropsychiatric disorders. Neurochem Res (1984) 0.82
Saccadic distractibility in cocaine dependent patients: a preliminary laboratory exploration of the cocaine-OCD hypothesis. Drug Alcohol Depend (1994) 0.82
Anxiety and pupil reactivity in cocaine dependent subjects endorsing cocaine-induced paranoia: preliminary report. Addiction (1995) 0.82
Dermatoglyphic study in autistic children and controls. J Am Acad Child Adolesc Psychiatry (1990) 0.81
Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol (1999) 0.81
Visual scanning of facial expressions in schizophrenia. J Neuropsychiatry Clin Neurosci (1999) 0.81
Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. Brain Res (1987) 0.81
Scheduled intermittent hospitalization for psychiatric patients. Psychiatr Serv (1998) 0.81
Subtype diagnosis in schizophrenia and its relation to neuropsychological and computerized tomography measures. Biol Psychiatry (1991) 0.81
Substance use diagnoses and discharge patterns among psychiatric inpatients. Hosp Community Psychiatry (1991) 0.81
Phenothiazine-induced lupus anticoagulant. J Clin Psychiatry (1992) 0.80
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol (1989) 0.80
Swim stress selectively alters the specific binding of a benzodiazepine antagonist in mice. Pharmacol Biochem Behav (1993) 0.80
Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol (2001) 0.80
Ultrastructural and enzymic modulation of HeLa cells induced by sodium butyrate and the effects of cytochalasin B and colcemid. J Cell Sci (1976) 0.80
Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin Neuropharmacol (1994) 0.79
Inbred mouse strains differ in sensitivity to "popping" behavior elicited by MK-801. Pharmacol Biochem Behav (1997) 0.79
Computerized measurement of MK-801-elicited popping and hyperactivity in mice. Clin Neuropharmacol (1995) 0.79
Violent antisocial behavior and Wisconsin Card Sorting Test performance in cocaine addicts. Am J Psychiatry (1993) 0.79
7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice. Neuropsychopharmacology (1996) 0.79
Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology (Berl) (1998) 0.79
The effects of milacemide on item and source memory. Clin Neuropharmacol (1992) 0.79
Concurrent psychiatric illness in inpatients with post-traumatic stress disorder. Mil Med (1989) 0.78
Baclofen treatment in a patient with tardive dystonia. J Clin Psychiatry (1986) 0.78
The relationship between cocaine-induced paranoia and compulsive foraging: a preliminary report. Addiction (1994) 0.78
Effects of nifedipine, a calcium channel antagonist, on cognitive function in schizophrenic patients with tardive dyskinesia. Clin Neuropharmacol (1997) 0.78
The antiseizure efficacies of MK-801, phencyclidine, ketamine, and memantine are altered selectively by stress. Pharmacol Biochem Behav (1997) 0.78
Predicting premorbid functioning in crack-cocaine abusers. Drug Alcohol Depend (1995) 0.78
An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol (1996) 0.78
Inbred mouse strains differ in their sensitivity to an antiseizure effect of MK-801. Clin Neuropharmacol (1998) 0.78
Plasma growth hormone response to oral l-dopa in infantile autism. J Autism Dev Disord (1985) 0.77
Rationale for the administration of opiate antagonists in treating infantile autism. Am J Ment Defic (1986) 0.77
Reactions of psychiatric staff to an AIDS patient. Am J Psychiatry (1985) 0.77
Visual scanning of faces correlates with schizophrenia symptomatology. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.77
Diethylpropion pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence: a test of the cocaine-agonist hypothesis. Clin Neuropharmacol (1995) 0.77
Glycine: a possible role in lithium's action and affective illness. Neuropsychobiology (1983) 0.77
Age of onset of affective illness. Psychiatr Clin (Basel) (1982) 0.77
Acromegaly and large cell lymphoma. Acta Haematol (1995) 0.77
Glycinergic interventions potentiate the ability of MK 801 to raise the threshold voltage for tonic hindlimb extension in mice. Pharmacol Biochem Behav (1992) 0.77
Memory for temporal order in schizophrenia. Biol Psychiatry (1991) 0.76
Limits of the processing view in accounting for dissociations among memory measures in a clinical population. Mem Cognit (1993) 0.76
Pupillary changes associated with the development of stimulant-induced mania: a case report. Clin Neuropharmacol (1997) 0.76
D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol (1996) 0.76
Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther (1989) 0.76
Differentiation between MK-801- and apomorphine-induced stereotyped behaviors in mice. Clin Neuropharmacol (1993) 0.76
Adrenalectomy prevents the stress-induced decrease in in vivo [3H]Ro15-1788 binding to GABAA benzodiazepine receptors in the mouse. Brain Res (1990) 0.76
Environmental stress-induced functional modification of the central benzodiazepine binding site. Clin Neuropharmacol (1994) 0.76
Thyroid hormone supplementation of fluoxetine treatment. J Clin Psychopharmacol (1990) 0.76
Evaluation of in vivo interactions in mice between flurazepam and two neuroactive steroids. Pharmacol Biochem Behav (1996) 0.76
Stress and a glycinergic intervention interact in the modulation of MK-801-elicited mouse popping behavior. Pharmacol Biochem Behav (1999) 0.76
Depot testosterone attenuates the anticonvulsant effect of flurazepam in mice. Psychoneuroendocrinology (1990) 0.76
Nimodipine pharmacotherapeutic adjuvant therapy for inpatient treatment of cocaine dependence. Clin Neuropharmacol (1994) 0.76
The competitive NMDA antagonist CPP blocks MK-801-elicited popping behavior in mice. Neuropsychopharmacology (1996) 0.76
Neuroleptic-related dyskinesias in autistic children: a prospective study. Psychopharmacol Bull (1985) 0.76
Effect of a low-tryptophan diet as an adjuvant to conventional neuroleptic therapy in schizophrenia. Clin Neuropharmacol (1992) 0.76
An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol (1990) 0.76
Fatigue in multiple sclerosis. Arch Neurol (1989) 0.75
Facilitating role of m-chlorophenylbiguanide in a cocaine discrimination. Pharmacol Biochem Behav (1995) 0.75
Depression dependent parkinsonism: case report. Int J Psychiatry Med (1986) 0.75
Apparent absence of famotidine-antipsychotic drug interactions in patients with chronic schizophrenia. J Psychiatry Neurosci (1996) 0.75
Specific cognitive deficits in neurologic and psychiatric disease: targets for treatment. Neurology (2000) 0.75
Frontal cortical atrophy and negative symptoms in patients with chronic alcohol dependence. J Neuropsychiatry Clin Neurosci (1997) 0.75
Benefits of routine laboratory investigations. Br J Psychiatry (1990) 0.75